1. Inzucchi SE, Bergenstal RM, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79. https://doi.org/10.2337/dc12-0413
2. American Diabetes Association. Pharmacologic therapy for type 2 Diabetes. Standards of Medical Care in Diabetes-2019. Diabetes Care, 2019. 42(Supplement 1): S90-S102. https://doi.org/10.2337/dc19-S009
3. Wexler DJ. Insulin therapy in DM type 2. Uptodate, 2020. https://www.uptodate.com/contents/insulin-therapy-in-type-2-diabetes-mellitus
4. Pettus J, Santos Cavaiola T, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32(6):478–96.
5. Heise T, Nosek L, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–50.
6. Jonassen I, Havelund S, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104–14.
7. Heise T, Hermanski L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859–64.
8. Pieber TR, Marso SP, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61(1):58–65.
9. Vora J, Christensen T, et a. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014 Dec;5(2):435-46.
10. Philis-Tsimikas A, Klonoff DC, et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia 63, 698–710 (2020). https://doi.org/10.1007/s00125-019-05080-9
11. Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017; 377:723-732
12. Zhou W, Tao J, et al. Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the management of Type 2 Diabetes: A systematic review and meta-analysis. Diabetes Ther.2019;10:835-852. https://doi.org/10.1007/s13300-019-0624-4
13. Goldenberg RM, Aroda VR, et al. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab. 2021 Nov;23(11):2572-2581.